Teva Pharmaceutical (TEVA) Announces Commercial Launch of Generic Allegra-D
More News related to SNY
- New GoMeals(TM) iPhone Application from sanofi-aventis U.S. to Help People with Diabetes Eat Healthy Anywhere, Anytime
- VerifyNow(R) System Highlighted in POPular Study Comparing Platelet Reactivity Tests
- Beacon Equity Issues Technical Trading Overview for Questcor Pharmaceuticals Inc.
- Trading Overview for Poniard Pharmaceuticals Inc. Issued by Beacon Equity
- Notable Analyst Rating Changes 11/16: COH, JWN, GNK, ESEA, SVA, YGE Upgraded; PARD, GPS, JCP, DLTR Downgraded
More News related to TEVA
- Protalix BioTherapeutics (PLX) Sees Interest On Renewed Takeover Talk
- Abbott (ABT) sues Teva (TEVA) over its drug for kidney patients, Zemplar
- Merriman Curhan Ford Initiates Coverage on Antares Pharma (AIS) with a Buy; Cutting Edge Drug Delivery Business
- Teva Pharma (TEVA) Gets Final U.S. FDA Approval for Generic Prevacid
- Teva Receives Final Approval for Generic Prevacid(R) Delayed-Release Capsules
More News related to Corporate News
- GE (GE) Said to Restart NBC Universal Acquisition Talks -WSJ
- Diedrich Coffee (DDRX) Comments on Green Mountain Coffee Roasters' (GMCR) Revised Offer
- Peet's (PEET) Issues Statement Following News Diedrich (DDRX) Says Green Mountain (GMCR) Revised Offer is 'Superior'
- Ericsson (ERIC) To Buy Assets of the Carrier Networks Division of Nortel for $70M
- Chaparral Energy and Refining Energy (URX) Amend Merger Agreement
Teva Pharmaceutical Industries Ltd. (Nasdaq: TEVA) announced today the commercial launch of Fexofenadine Hydrochloride 60 mg and Pseudoephedrine Hydrochloride 120 mg Extended-Release Tablets, the same as the sanofi-aventis (NYSE: SNY) U.S. allergy treatment Allegra-D(R) 12 Hour (fexofenadine HCl 60 mg and pseudoephedrine HCl 120 mg) Extended-Release Tablets. Teva's product is an alternative to the brand product, which had annual sales of approximately $293 million in the United States for the twelve months that ended June 30, 2009, based on IMS sales data.
As the first company to file an ANDA containing a paragraph IV certification for this product, Teva has been awarded a 180-day period of marketing exclusivity in the U.S.
Teva is distributing the product, under a license agreement entered into between Teva's subsidiary Barr Pharmaceuticals, Inc. and sanofi-aventis U.S. Allegra-D is a registered trademark of sanofi-aventis U.S.
[SM]
Related Categories
Corporate NewsStocks Mentioned
+0.84
-0.11Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
